Shamburg News · 8-K filed Nov 13, 2026, 6:27 AM EST

Rezolute Reports Positive Phase 3 upLIFT Results in Tumor Hyperinsulinism

RZLT · Rezolute, Inc.

  • Reg FD disclosure
  • Other event
  • Other
  • Materiality: high

On November 13, 2026, Rezolute, Inc. announced positive interim results from the ongoing open-label Phase 3 upLIFT study of ersodetug in tumor hyperinsulinism, stating the primary efficacy endpoint has been achieved based on preliminary results from a November 5 data evaluation. The company reported that 13 of 16 enrolled participants have met the responder criterion, including 12 who also achieved complete discontinuation of IV glucose. Full topline results, including statistical analysis of the primary endpoint, are expected by mid-December 2026.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 7.01, 8.01, 9.01, accession 0001104659-26-126502.

Written from the filing by Shamburg Markets. Figures are as reported by the company.